Determining which cancer patients are a good candidate for immune checkpoint inhibitors can be a challenge, but researchers at Mount Sinai and Memorial Sloan Kettering Cancer Center have developed a promising tool to predict which patients will respond well to the therapy.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
